Unknown

Dataset Information

0

DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes.


ABSTRACT: More precise identification and treatment monitoring of prediabetic/diabetic individuals will require additional biomarkers to complement existing diagnostic tests. Candidates include hyperglycemia-induced adducts such as advanced glycation end products (AGEs) of proteins, lipids, and DNA. The potential for DNA-AGEs as diabetic biomarkers was examined in a longitudinal study using the Leprdb/db animal model of metabolic syndrome. The DNA-AGE, N2-(1-carboxyethyl)-2'-deoxyguanosine (CEdG) was quantified by mass spectrometry using isotope dilution from the urine and tissue of hyperglycemic and normoglycemic mice. Hyperglycemic mice (fasting plasma glucose, FPG, ? 200 mg/dL) displayed a higher median urinary CEdG value (238.4 ± 112.8 pmol/24 h) than normoglycemic mice (16.1 ± 11.8 pmol/24 h). Logistic regression analysis revealed urinary CEdG to be an independent predictor of hyperglycemia. Urinary CEdG was positively correlated with FPG in hyperglycemic animals and with HbA1c for all mice. Average tissue-derived CEdG was also higher in hyperglycemic mice (18.4 CEdG/106 dG) than normoglycemic mice (4.4 CEdG/106 dG). Urinary CEdG was significantly elevated in Leprdb/db mice relative to Leprwt/wt, and tissue CEdG values increased in the order Leprwt/wt < Leprwt/db < Leprdb/db. These data suggest that urinary CEdG measurement may provide a noninvasive quantitative index of glycemic status and augment existing biomarkers for the diagnosis and monitoring of diabetes.

SUBMITTER: Jaramillo R 

PROVIDER: S-EPMC5346351 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes.

Jaramillo Richard R   Shuck Sarah C SC   Chan Yin S YS   Liu Xueli X   Bates Steven E SE   Lim Punnajit P PP   Tamae Daniel D   Lacoste Sandrine S   O'Connor Timothy R TR   Termini John J  

Chemical research in toxicology 20170203 2


More precise identification and treatment monitoring of prediabetic/diabetic individuals will require additional biomarkers to complement existing diagnostic tests. Candidates include hyperglycemia-induced adducts such as advanced glycation end products (AGEs) of proteins, lipids, and DNA. The potential for DNA-AGEs as diabetic biomarkers was examined in a longitudinal study using the Lepr<sup>db/db</sup> animal model of metabolic syndrome. The DNA-AGE, N<sup>2</sup>-(1-carboxyethyl)-2'-deoxygua  ...[more]

Similar Datasets

| S-EPMC2989594 | biostudies-literature
| S-EPMC4904211 | biostudies-literature
| S-EPMC6146089 | biostudies-literature
| S-EPMC9971228 | biostudies-literature
| S-EPMC9029922 | biostudies-literature
| S-EPMC7104326 | biostudies-literature
| S-EPMC5752849 | biostudies-literature
| S-EPMC4571620 | biostudies-literature
| S-EPMC4038343 | biostudies-literature
| S-EPMC5589639 | biostudies-literature